Ascletis Pharma, Inc. (HK:1672) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascletis Pharma Inc. has reported a significant increase in loss for the six-month period ending June 30, 2024, compared to the same period in 2023, primarily due to higher research and development costs. The company saw a complete loss of revenue during the period, attributing it to a decrease in market demand for its ritonavir product amidst effective COVID-19 control in Mainland China. Despite financial setbacks, Ascletis Pharma made notable progress in several clinical trials, including positive results for treatments of NASH and acne vulgaris.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.